PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability

Gastric adenocarcinoma is the second leading cause of cancer death worldwide, following lung cancer. The five-year survival rate of advanced metastatic disease is low. Combination chemotherapy results in improvement in overall survival in comparison with single-agent treatment or supportive care (1,2). Limited progress has been made by adding targeted therapy to the treatment of gastric cancer. The only two targeted agents approved by the US Food and Drug Administration (FDA) are ramucirumab (3,4), a VEGF antibody, and trastuzumab (5), which is indicated only in tumors with amplified human epidermal growth factor receptor 2 (Her-2). Both drugs have a modest impact on overall survival.

http://ift.tt/2z40Beu